Snapshot from Jul 27, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Avacta appoints Patrick Vink Deputy Chairman
Business board appointment

Avacta appoints Patrick Vink Deputy Chairman

Analysis based on 7 articles · First reported Jul 08, 2026 · Last updated Jul 08, 2026

Sentiment
10
Attention
1
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The appointment of a seasoned executive may strengthen Avacta's board and support its pipeline advancement. However, the event is unlikely to have significant immediate market impact.

biotechnology pharmaceuticals
Event Summary

Avacta Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Dr. Patrick Vink as Non-Executive Deputy Chairman and Senior Independent Director. Dr. Vink is a seasoned healthcare executive with experience at Cubist Pharmaceuticals, Sanofi, Biogen, Novartis — Sandoz, and Mylan. He currently serves as Chairman at Arch Biopartners and on the board of Spero Therapeutics. The appointment is effective July 8, 2026.

Key Actions
70 Avacta Group appointed Patrick Vink
Entities Involved
stock
Avacta Group
Avacta appointed Patrick Vink as Deputy Chairman, adding board expertise.
Importance 100.0 Sentiment 10.0
per
Patrick Vink
Patrick Vink was appointed as Deputy Chairman of Avacta.
Importance 100.0 Sentiment 10.0
per
Christina Coughlin
Christina Coughlin, CEO of Avacta, welcomed the appointment.
Importance 50.0 Sentiment 10.0
stock
Arch Biopartners
Patrick Vink serves as Chairman of Arch Biopartners.
Importance 10.0 Sentiment 0.0
stock
Spero Therapeutics
Patrick Vink serves on the board of Spero Therapeutics.
Importance 10.0 Sentiment 0.0
subs
Merck & Co. — Cubist Pharmaceuticals
Patrick Vink previously served as EVP and COO at Cubist Pharmaceuticals.
Importance 10.0 Sentiment 0.0
priv
Micreos Group
Patrick Vink is Chairman of Micreos Group.
Importance 5.0 Sentiment 0.0
priv
Secura Bio
Patrick Vink is Chairman of Secura Bio.
Importance 5.0 Sentiment 0.0
priv
F2G
Patrick Vink is Chairman of F2G.
Importance 5.0 Sentiment 0.0
priv
Athyrium Capital Management
Patrick Vink is a senior advisor to Athyrium Capital Management.
Importance 5.0 Sentiment 0.0
priv
Forbion Ventures
Patrick Vink is a senior advisor to Forbion Ventures.
Importance 5.0 Sentiment 0.0
stock
Merck & Co.
Merck acquired Cubist Pharmaceuticals.
Importance 5.0 Sentiment 0.0
stock
Sanofi
Patrick Vink started his career at Sanofi.
Importance 5.0 Sentiment 0.0
stock
Biogen
Patrick Vink held senior executive roles at Biogen.
Importance 5.0 Sentiment 0.0
subs
Novartis — Sandoz
Patrick Vink held senior executive roles at Novartis — Sandoz.
Importance 5.0 Sentiment 0.0
+ 7 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.